Gain Therapeutics
GANX
24 hedge funds and large institutions have $5.68M invested in Gain Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 2 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
159% more call options, than puts
Call options by funds: $331K | Put options by funds: $128K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
9% more funds holding
Funds holding: 22 → 24 (+2)
2% more capital invested
Capital invested by funds: $5.54M → $5.68M (+$134K)
0.61% more ownership
Funds ownership: 9.68% → 10.28% (+0.61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$267K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$217K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$91.8K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$65.4K |
| 5 |
Millennium Management
New York
|
+$61.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$92.5K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$67.8K |
| 3 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
-$60.3K |
| 4 |
CC
Cannell Capital
Alta,
Wyoming
|
-$59.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.2K |
GANX Hedge Fund Activity: Q2 2023 in Review
24 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q2 2023, worth a combined $5.68M — up 2.4% from $5.54M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GANX positions and 2 closed out — a net gain of 2 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $267K. The largest seller was Royal Bank of Canada, cutting an estimated $92.5K.
- 24 institutional investors held Gain Therapeutics (GANX) as of Q2 2023, up from 22 in Q1 2023.
- Funds reported $5.68M of Gain Therapeutics stock for Q2 2023, up 2.4% quarter-over-quarter.
- 4 funds opened new Gain Therapeutics positions in Q2 2023 and 2 closed out, a net change of +2 holders.
- The largest Gain Therapeutics buyer in Q2 2023 was Susquehanna International Group, an estimated $267K added.
- The largest Gain Therapeutics seller in Q2 2023 was Royal Bank of Canada, an estimated $92.5K sold.
Based on aggregated 13F filings for Q2 2023.